New horizons in lung cancer management through ATR/CHK1 pathway modulation

Riya Thapa; Obaid Afzal; Asif Ahmad Bhat; Ahsas Goyal; Abdulmalik Saleh Alfawaz Altamimi; Waleed Hassan Almalki; Sami I. Alzarea; Imran Kazmi; Sachin Kumar Singh; Kamal Dua; Lakshmi Thangavelu; Gaurav Gupta

doi:10.4155/fmc-2023-0164

New horizons in lung cancer management through ATR/CHK1 pathway modulation

Riya Thapa, Obaid Afzal, Asif Ahmad Bhat, Ahsas Goyal, Abdulmalik Saleh Alfawaz Altamimi, Waleed Hassan Almalki, Sami I. Alzarea, Imran Kazmi, Sachin Kumar Singh, Kamal Dua, Lakshmi Thangavelu, Gaurav Gupta

Pharmaceutical Chemistry

Research output: Contribution to journal › Review article › peer-review

67 Scopus citations

Abstract

Lung cancer is the leading cause of cancer-related deaths worldwide. Molecular profiling has contributed to a new classification of lung cancer, driving advancements in research and therapy. The ataxia telangiectasia and rad3/checkpoint kinase 1 (ATR/CHK1) pathway plays a crucial role in maintaining genomic stability, and its activation has been linked to the development of lung cancer, drug resistance and poor prognosis. Clinical and preclinical studies have demonstrated promising results in targeting this pathway. ATR and CHK1 are proteins that collaborate to repair DNA damage caused by radiation or chemotherapy. ATR/CHK1 inhibitors are currently under investigation in preclinical and clinical trials. This article explores the ATR/CHK1 pathway and its potential for treating lung cancer.

Original language	English
Pages (from-to)	1807-1818
Number of pages	12
Journal	Future Medicinal Chemistry
Volume	15
Issue number	19
DOIs	https://doi.org/10.4155/fmc-2023-0164
State	Published - 1 Oct 2023

Keywords

ATR
CHK1
DNA damage
NSCLC
SCLC
cancer
lung cancer

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.4155/fmc-2023-0164

Cite this

@article{4310eba8dee64c62a394d9c61ab7e204,

title = "New horizons in lung cancer management through ATR/CHK1 pathway modulation",

abstract = "Lung cancer is the leading cause of cancer-related deaths worldwide. Molecular profiling has contributed to a new classification of lung cancer, driving advancements in research and therapy. The ataxia telangiectasia and rad3/checkpoint kinase 1 (ATR/CHK1) pathway plays a crucial role in maintaining genomic stability, and its activation has been linked to the development of lung cancer, drug resistance and poor prognosis. Clinical and preclinical studies have demonstrated promising results in targeting this pathway. ATR and CHK1 are proteins that collaborate to repair DNA damage caused by radiation or chemotherapy. ATR/CHK1 inhibitors are currently under investigation in preclinical and clinical trials. This article explores the ATR/CHK1 pathway and its potential for treating lung cancer.",

keywords = "ATR, CHK1, DNA damage, NSCLC, SCLC, cancer, lung cancer",

author = "Riya Thapa and Obaid Afzal and Bhat, \{Asif Ahmad\} and Ahsas Goyal and \{Alfawaz Altamimi\}, \{Abdulmalik Saleh\} and Almalki, \{Waleed Hassan\} and Alzarea, \{Sami I.\} and Imran Kazmi and Singh, \{Sachin Kumar\} and Kamal Dua and Lakshmi Thangavelu and Gaurav Gupta",

note = "Publisher Copyright: {\textcopyright} 2023 Newlands Press.",

year = "2023",

month = oct,

day = "1",

doi = "10.4155/fmc-2023-0164",

language = "English",

volume = "15",

pages = "1807--1818",

journal = "Future Medicinal Chemistry",

issn = "1756-8919",

publisher = "Taylor and Francis Ltd.",

number = "19",

}

TY - JOUR

T1 - New horizons in lung cancer management through ATR/CHK1 pathway modulation

AU - Thapa, Riya

AU - Afzal, Obaid

AU - Bhat, Asif Ahmad

AU - Goyal, Ahsas

AU - Alfawaz Altamimi, Abdulmalik Saleh

AU - Almalki, Waleed Hassan

AU - Alzarea, Sami I.

AU - Kazmi, Imran

AU - Singh, Sachin Kumar

AU - Dua, Kamal

AU - Thangavelu, Lakshmi

AU - Gupta, Gaurav

PY - 2023/10/1

Y1 - 2023/10/1

N2 - Lung cancer is the leading cause of cancer-related deaths worldwide. Molecular profiling has contributed to a new classification of lung cancer, driving advancements in research and therapy. The ataxia telangiectasia and rad3/checkpoint kinase 1 (ATR/CHK1) pathway plays a crucial role in maintaining genomic stability, and its activation has been linked to the development of lung cancer, drug resistance and poor prognosis. Clinical and preclinical studies have demonstrated promising results in targeting this pathway. ATR and CHK1 are proteins that collaborate to repair DNA damage caused by radiation or chemotherapy. ATR/CHK1 inhibitors are currently under investigation in preclinical and clinical trials. This article explores the ATR/CHK1 pathway and its potential for treating lung cancer.

AB - Lung cancer is the leading cause of cancer-related deaths worldwide. Molecular profiling has contributed to a new classification of lung cancer, driving advancements in research and therapy. The ataxia telangiectasia and rad3/checkpoint kinase 1 (ATR/CHK1) pathway plays a crucial role in maintaining genomic stability, and its activation has been linked to the development of lung cancer, drug resistance and poor prognosis. Clinical and preclinical studies have demonstrated promising results in targeting this pathway. ATR and CHK1 are proteins that collaborate to repair DNA damage caused by radiation or chemotherapy. ATR/CHK1 inhibitors are currently under investigation in preclinical and clinical trials. This article explores the ATR/CHK1 pathway and its potential for treating lung cancer.

KW - ATR

KW - CHK1

KW - DNA damage

KW - NSCLC

KW - SCLC

KW - cancer

KW - lung cancer

UR - http://www.scopus.com/inward/record.url?scp=85175660585&partnerID=8YFLogxK

U2 - 10.4155/fmc-2023-0164

DO - 10.4155/fmc-2023-0164

M3 - Review article

C2 - 37877252

AN - SCOPUS:85175660585

SN - 1756-8919

VL - 15

SP - 1807

EP - 1818

JO - Future Medicinal Chemistry

JF - Future Medicinal Chemistry

IS - 19

ER -

New horizons in lung cancer management through ATR/CHK1 pathway modulation

Abstract

Keywords

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this